Research programme: radioligand therapies - Oncodesign Precision Medicine/Undisclosed company
Latest Information Update: 18 Aug 2024
At a glance
- Originator Oncodesign Precision Medicine; Undisclosed Company
- Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 29 Jul 2024 Early research in Cancer (Diagnosis) in France (unspecified route)
- 29 Jul 2024 Early research in Cancer in France (unspecified route) (Oncodesign Precision Medicine pipeline; July 2024)